Building On Successes During Turbulent Times, SR One Closes $600m Fund II
$1.1bn Raised Since Spinning Out Of GSK
SR One will keep investing in a mix of new companies, early-stage firms and later opportunities with its second fund, raised even as biotech continues to endure challenging financial times.
